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Objectives: Cancer cachexia is characterised by a progressive loss of muscle, resulting 
in functional impairment and shorter survival. Therefore, omega-3 has been studied for 
its role as an anti-cachectic therapy. This systematic review identified studies published 
on use of omega-3 in cancer cachexia in order to examines the potential benefit. 
Methods: A systematic literature search of the PubMed database and B-on database 
was conducted in March 2015 to identify studies published between 2000 and 2015. Of 
140 publications, 7 were selected on the basis of their methodological quality, according 
to the Delphi List. The collected data was summarized and written in text format and in 
tables. Results: Only one study, made in precachectic population, show statistically and 
clinically positive intervention. No benefits were observed with the 4g EPA/day, but a 
potentially clinically relevant treatment effect with 2g EPA/day. Lung tumors showed 
the highest CRP levels and while the weight of patients with gastrointestinal cancer 
increased significantly, patients with lung cancer showed no significant response. 
Conclusions: Future cachexia trials would likely benefit from studying a single tumor 
type with earlier stage disease, with probably different dosage depending on the type 
and inflammation profile.  
 
Resumo 
Objetivos: A caquexia do cancro caracteriza-se por uma progressiva perda de massa 
muscular, que resulta num prejuízo funcional e numa diminuição da sobrevida. Tendo 
isso em conta, tem sido estudado o papel do ómega-3 na terapêutica da caquexia. Esta 
revisão sistemática identificou os estudos publicados acerca do uso do ómega-3 na 
caquexia do cancro por forma a identificar o potencial beneficio. Métodos: Uma 
pesquisa sistemática da literatura na base de dados PubMed e B-on foi realizada em 
Março de 2015, por forma a identificar estudos publicados entre 2000 e 2015. Das 140 
publicações, 7 foram selecionadas com base na sua qualidade metodológica, de acordo 
com a Lista de Delphi. A informação obtida foi resumida e escrita em formato de texto 
e tabelas. Resultados: Apenas um estudo, realizado numa população pré-caquética, 
revelou a intervenção como sendo estatisticamente e clinicamente positiva. Não foram 
observados benefícios com 4g de EPA/dia, mas um potencial efeito clinicamente 
relevante foi observado com 2g de EPA/dia. O cancro do pulmão demonstrou os níveis 
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de PCR mais elevados e enquanto que o peso dos doentes com cancro gastrointestinal 
aumentou significativamente, os doentes com cancro do pulmão não demonstraram uma 
resposta significativa. Conclusões: Futuros ensaios acerca da caquexia poderiam 
provavelmente beneficiar em estudar um único tipo de tumor, em estádios mais 























A systematic literature search of the PubMed database and B-on database was 
conducted in March 2015 to identify studies published on use of omega-3 in cancer 
cachexia. The following search terms were used: “omega 3+treatment of cancer”, 
“omega 3+cachexia” and “omega 3+nutricional state+cancer”. There was time 
restriction, between 2000 and 2015. In the PubMed database one filter was used: 
“humans”. A total of 140 records were identified. Three of these in duplicated form and 
were removed. From 137 screened, 41 full text articles were assessed eligibility criteria, 
103 were excluded and 34 were included. From included, 2 were “systematic review”, 
10 were “review”, 8 were “others” (theoretical records, comments) and 14 were 
“clinical trial”.  
Studies were included if: 1) humans; 2) evaluate the following outcomes: weight 
and/or body composition and/or nutritional state and/or quality of life; 3) use of omega-
3 in cancer patients. Studies were excluded if: 1) evaluate solely the effect in tumor 
progression and/or in emergence of metastasis and/or in enhancing chemo or 
radiotherapy effect; 2) association of omega-3 with another substance which is not also 
present in controlled group. 
 
Study quality 
The methodological quality of the 14 selected studies was evaluated using the 
Delphi List (Jadad et al 1996). Below 3 points the study is considered as having low 
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Fatty acids, once solely thought as an energy source, have been shown to be 
highly active substances. They can act as transcription factors that regulate protein 
synthesis as ligands in signal transduction, and as membrane components that regulate 
the fluidity, permeability, and dynamics of cell membranes (2). There are 3 types of 
naturally occurring fats: saturated, monounsaturated and polyunsaturated (1). The bonds 
between carbons in saturated fatty acids are fully saturated with hydrogen and are single 
bonds. Monounsaturated fatty acids and polyunsaturated fatty acids (PUFAs) have 
bonds that are not saturated with hydrogen, thus one or more double bonds connect the 
molecule carbons (6).  
Omega-3 fatty acids 
Polyunsaturated fats can be classified into 2 groups based on the position of the 
first double bond site: omega-3 fatty acids or omega-6 fatty acids (1). Mammals, 
including humans, can synthesize saturated fatty acids and monounsaturated (n-9) ones, 
but cannot synthesize either the (n-6) or the (n-3) double bond fatty acids (6). The most 
prominent omega-6 fatty acids in the human diet are arachidonic acid (AA) (found in 
animal meat) and linoleic acid (LA) (found in vegetable oils, seeds, nuts), which can be 
converted in arachidonic acid by desaturase enzyme (1). 
Major dietary sources of omega-3 are fatty fish such as mackerel, herring, 
salmon, sardines, pilchards and kippers containing eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) (5), as well as nuts, seeds, and vegetable oils containing 
α-linolenic acid (ALA) that can be converted into EPA and then DHA by the same 
desaturase enzyme (1). Isotope-labelled ALA feeding trials have shown the conversion 
of ALA to EPA to vary from 0.2% to 21% and that of ALA into DHA to vary between 
0% and to 9% (1). 
ALA does not usually accumulate to particularly high concentrations even when 
ingested at relatively high dietary levels. This is partly due to the fact that much of the 
dietary ALA undergoes β-oxidation in the mitochondria and very limited amount is 
available for its conversion to EPA and DHA. (3) It is also known that increased 





The ratio of omega-6/omega-3 intake is estimated to be 20 to 1 in the modern 
Western diet, compared with that of our palaeolithic ancestors who ate a diet much 
richer in omega-3’s: estimated omega-3/omega-6 ratio of 2:1 (1). Nowadays, meat and 
fish contain less omega-3 and more omega-6 fatty acids than in the past, secondary to 
the use of commercial rations with high content of omega-6 and low in omega-3. Even 
cultivated vegetables are poorer in omega-3 when compared with wild plants (1). About 
95-99% of the population eats lesser than the required  ω-3 fatty acids for a good health 
(3). The metabolism of omega-3’s and omega-6’s leads to the creation of the 
metabolites named eicosanoids that are a class of bioactive molecules, which include 
prostaglandins, thromboxanes (due to COX activity) and leukotrienes (due to LOX) (1, 
5). Eicosanoids derived from omega-6’s are 2-series prostanoids (thromboxane A2, 
prostaglandin E2 and prostacyclin2) and 4-series leukotrienes (leukotriene B4 and 
leukotriene C4) and are generally pro-inflammatory and pro-aggregation, whereas those 
derived from omega-3’s are 3-series prostanoids and 5-series leukotrienes and are 
predominantly anti-inflammatory and inhibit platelet aggregation (1, 5, 6). 
Adverse effects of EPA and other n-3 fatty acids were reported in few studies. 
Most usual gastrointestinal effects are mild abdominal discomfort, flatulence or nausea, 
transient diarrhoea or steatorrhoea. Some studies reported fish aftertaste (4). Presently, a 
number of alternative sources of omega-3 fatty acids have been or are being developed. 
For example, oils naturally enriched in DHA are being extracted from cultured 
microorganisms like the algae Crypthecodinium cohnii and are now being used to 
fortify a number of products, including baby formula. Similarly, novel plants like 
Echium plantagineum are being cultivated because their seed oil naturally contains 
stearidonic acid, an intermediate in the metabolism of omega-3 fatty acids, that appears 
to be metabolized much more efficiently than α-linolenic acid, resulting in an 
enrichment of tissues with EPA and DHA following its consumption. Finally, a number 
of companies have developed transgenic varieties that can produce seed oils that are 
highly enriched with stearidonic, EPA and DHA acids (7). 
 
Cancer cachexia 
Cancer-induced cachexia (CIC) is experienced by up to 80% of patients with 
advanced cancer, particularly those with gastrointestinal, pancreatic, and head-neck 
malignancies. CIC has been implicated in up to 20% of cancer-related deaths (9). The 
8 
 
European Palliative Care Research Collaborative (EPCRC) has defined CIC as follows: 
“Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal 
muscle mass (with or without loss of fat mass) that cannot be fully reversed by 
conventional nutritional support and leads to progressive functional impairment” (4). 
Besides that, cachexia can be also characterised by anorexia, early satiety, changes in 
taste perception, weight loss, weakness, anaemia and oedema, all affecting appetite and 
diet (5). Fearon et al have proposed a clinical definition of CIC supported by the latest 
research that included three factors: weight loss >10%, low caloric intake <1500 
kcal/day, and systemic inflammation as measured by a CRP >10 mg/L (9).  
It is also known that weight loss negatively affects patient’s ability to tolerate 
chemotherapy and radiotherapy, and weight loss approaches 30% of baseline pre-
treatment weight (9). There is an association between cachexia and shorter survival as 
well as poor Quality of Life (QoL) (5). Multiple biologic pathways are involved in this 
process, including immune response, neuroendocrine hormones and tumour specific 
factors such as proteolysis inducing factor (PIF) (10). The immune response consists in 
increased immunological factors such as the cytokines interleukin-1 (IL-1), interleukin-
6 (IL-6), Interferon γ (IFN-) and Tumour Necrosis Factor-Alpha (TNF-α) (5). These 
cytokines have been found to lead to hypermetabolism and increased hepatic amino acid 
uptake and protein synthesis: acute-phase proteins, such as CRP, fibrinogen, and serum 
amyloid peptide (5, 9). They are also responsible for accelerated muscle and adipose 
tissue breakdown, induction of gluconeogenesis, activation of NF-κB and stimulation of 
the production of arachidonic metabolites. On the other hand, leukotriene B4 and 
thromboxane A2 are considered stimulators of TNF-α and IL-1 production (5, 9).  
Of note that many studies have attributed the cause of muscle proteolysis to the 
ubiquitin-proteasome pathway and to a dysregulation of the dystrophin glycoprotein 
complex (DGC). Initiated by NF-κB, ubiquitin molecules attach to a muscle protein 
marking it for degradation in the large tube-like proteasome. The DGC is a collection of 
proteins that anchors muscle sarcomeres and protects them during muscle contraction 
(9). For these reasons, cytokines are regarded as the driving force behind cancer 
cachexia and are considered to be both tumour and host derived (5). 
Neuroendocrine hormones, e.g. leptin, ghrelin, and serotonin, when reaching the 
brain hypothalamic region, play a central role in balancing the orexigenic and 
anorexigenic signals. Their cytokine-driven dysregulation lead to decreased food intake 
and increased resting energy expenditure (REE) (11). 
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On the other hand, a tumour product, PIF, initiates muscle protein degradation directly 
through activation of the proteasome pathway (12). One single therapy may not be 
completely successful in the treatment of cachexia. Treatments involving different 
combinations are more likely to be successful (11). 
 
Omega-3 and cachexia 
Omega-6 arachidonic acid (AA) and the cyclooxygenase-2 (COX-2) enzyme are 
both found in abundance in most cancer tissues, but the concentrations of omega-3 fatty 
acids DHA and EPA are usually lower compared to normal tissues (2). Beneficial 
effects may be mediated through several different mechanisms, including alteration in 
cell membrane composition, gene expression or eicosanoid production (3). Dietary 
omega-3 fatty acids directly affect AA metabolism because they displace AA from 
membranes and compete with AA for the enzymes that catalyse the biosynthesis of 
eicosanoids. The enrichment of monocyte membranes with omega-3 fatty acids results 
in the synthesis and secretion of reduced quantities of cytokines (e.g. TNF-α, IL-1β) (5, 
7, 13). Recent studies have shown that n-3 fatty acids may attenuate protein 
degradation, potentially by preventing NF-kB accumulation in the nucleus, preventing 
the degradation of muscle proteins (12). Furthermore, the effects of PIF are also 
inhibited by EPA (10). This suggest that n-3 PUFAs may have an important role in 
nutritional support of cancer patients if they can be administered in such a way that high 
doses can be achieved for prolonged periods of time with limited gastrointestinal side 
effects (13), Table 1.  
Reported positive outcomes related to cachexia include diminished weight loss, 
increased appetite, improved Quality of Life and prolonged survival in weight-losing 
cancer patients (5), Table 1. Besides acting in cachexia, several experimental studies 
have reported an association between dietary fish oil and attenuation of side effects of  
anti-neoplastic therapies and enhanced cytotoxicity of drugs in tumour cells (9). 
However, some trials failed to show a significant benefit in cachexia, Table 2. There are 
several reasons for discordance, including the time at which intervention was initiated 
(early or later stages), contamination between treatment arms (9), selection of primary 
outcome markers such as weight, which has been shown to be confounded by hydration 
(12) and indirect assessments of muscle mass (9). Most studies used bioelectrical 
impedance analysis for assessment of the body composition. Measurement works well 
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in healthy subjects with stable water and electrolyte balance. However, it is not 
validated for patients with extreme BMI ranges or with abnormal hydration, where it 
can both over- or underestimate muscle mass significantly (4). 
Moreover, patients with advanced cancer are often unable to complete the study 
intervention time and are unable to consume the therapeutic dose of omega-3 fatty acids 
due to anorexia, dysgeusia or dysphagia from chemotherapy and radiation (9). 
Megestrol Acetate (MA) is a synthetic derivate of progesterone (9) and is currently 
considered the best available treatment option for cancer-related cachexia, and it is the 
only drug approved in Europe (11). Studies show that various doses of MA stimulate 
appetite and increase weight gain (9) by inducing the release of neuropeptide Y in the 
CNS (11). However, less than 30% of patients experience short-term appetite 
stimulation (11) and more detailed body composition studies suggest that the weight 
gain is largely an increase in fat mass, while performance status and QoL are generally 






Table 1. Statistically and clinically positive intervention studies with EPA and/or DHA and outcomes  
Author 
(year) 
Population and study 
design 








Lung cancer (stage IIIa-N2 
or IIIb NSCLC) 
Double-blind, randomized, 
controlled trial 
Intervention group: 2 cans/day of fish-
oil enriched oral nutritional 
supplement, energy+protein-dense 
(2.02g/day EPA+0.92g/day DHA); 
Control group: isocaloric oral 
nutritional supplement without 
EPA+DHA; 
Follow-up during 5 weeks from the 
start of concurrent chemoradiotherapy; 
Weight 




EPA group: weight maintenance (weight 
difference between intervention group and 
control group: 1.3 kg, p=0.02 at 2 weeks and 1.7 
kg, p=0.04 at 4 weeks); 
Less decrease in FFM (FFM difference between 
intervention group and control group (1.5 kg at 3 
weeks (p=0.05) and 1.9 kg at 5 weeks (p=0.02)); 
Increased MUAMC, while the MUAMC in the 
control group decrease (difference between 
groups not significant at 5 weeks p=0.06). 
Compared with the C group, the REE in the I 
group decreased more after 3 weeks (B= -16.7% 








Lung cancer (stage IIIa-N2 
or IIIb NSCLC) 
Double-blind, randomized, 
controlled trial 
Intervention group: 2 cans/day of fish-
oil enriched oral nutritional 
supplement, energy+protein-dense 
(2.02g/day EPA+0.92g/day DHA); 
Control group: isocaloric oral 
nutritional supplement without 
EPA+DHA; 
Follow-up during 5 weeks from the 
start of concurrent chemoradiotherapy; 














After 3 weeks, the I group had a higher 
Karnofsky Performance Status than the C group 
(p= 0.04) and after 5 weeks, showed a 
significantly better global health status, physical 
function, cognitive function and social function 
on the EORTC (p= 0.04, p<0.01, p<0.01, p= 
0.04); 
During week 3 and 5, the I group tended to have 
a higher daily physical activity score (p= 0.04, p= 
0.05); 
Handgrip strength did not significantly differ 




Table 2. Statistically and clinically negative intervention studies with EPA and/or DHA or echium oil and outcomes 
Author(year) Population and study 
design 
Intervention Outcomes Results 




(9 in intervention vs. 15 





Intervention group: fish-oil enriched 
oral nutritional supplement 2 cans/day 
(2,2g EPA + 0.96g DHA/day) 
Control group: identical oral nutritional 
supplement without n-3 fatty acids. 
Follow-up at 8 weeks from baseline 
Weight 
BIA: LBM 





TEE, PAL and EEA 
(DLW, doubly 
labelled water) 
No significant changes in weight or LBM in 
either group over 8 weeks of 
supplementation vs. baseline values. 
No statistically significant differences 
between groups in REE, TEE, PAL and 
EEA. However, when compared with 
baseline values, TEE, EEA and PAL 
increased significantly in intervention 
group; 
Jatoi, et al 
2004 
(17) 





blind, randomized trial 
3 groups: EPA supplement (refined, 
deodorized sardine oil, with 1.09g of 
EPA and 0.46g of docosahexaenoic 
acid), 2 cans/day + placebo; MA, 
600mg/day + isocaloric, isonitrogenous 
placebo; EPA supplement, 2 cans/day + 
MA 600 mg/day. 








Global quality of life 
(Uniscale) 
No significant change in weight with EPA 
alone or in combination with MA. 6% 
patients taking EPA supplement gained 
≥10% baseline weight vs 18% of patients 
taking MA (p=0.01). MA alone was more 
effective for weight gain: 1.3 kg vs -1.0 kg 
in the EPA-treated arm, p=0.008 
However, when weight gain was evaluated 
with increments of less than 10% weight 
increase, there seemed to be no significant 
differences among the arms; 
Appetite, as measured by the NCCTG, 
showed comparable effect among groups. 
The FAACT suggest that MA provided 
better appetite stimulation than EPA alone 
(p=0.004); 
There were no statistically significant 
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differences in median survival and in 
quality of life (p=0.82 and p=0.93 
respectively); 











Intervention group: 1g soft gelatin 
capsules of 95% EPA diester; Two 
EPA doses tested: 2g EPA/day and 4g 
EPA/day; 
Control group: medium chain 
triglycerides; 
Follow-up at 8 weeks from baseline; 
Weight (spring 















No statistical difference for weight and 
LBM between groups (p=0.066 and p=0.14, 
respectively); 
By comparison with control group, the 
group receiving 2g EPA/day had a mean 
increase of 1.2 kg of weight and of 0.9 kg 
of LBM and group receiving 4g EPA had a 
mean increase of 0.3kg of weight and a 
mean decrease of 0.1 kg of LBM; 
There was a statistically significant 
difference in physical function, which 
improved by 7% in those receiving 2g EPA 
(p=0.04) and fell 5% in those receiving 4g 
EPA; 
Weakness tended to decrease in the 2g 
EPA; 
Median survival: 140 days (placebo), 155 
(2g EPA), 142 (4g EPA); 













Intervention group: three 125 mL units 
of ONS enriched with EPA (600kcal, 
33g protein and 2,2g EPA) per day; 
Control group: two 200mL units of 
standart ONS (600kcal, 24g protein) 
per day; 
Start 3 days before first chemotherapy 




In the intention-to-treat analysis (57 pats) 
and in protocol analyses (43 pats) there was 
not significant difference between 
intervention group and control group in 
CRP values (-0.5 mg/dL vs. -0.7 
mg/dL(p=0,6) and -2.35 mg/dL vs. -0.7 
mg/dL(p=0,8) respectively); 
There is however a nonsignificant trend 
14 
 
blind, controlled trial; baseline; toward a decrease in the EPA group; 





carcinoma of the head 
and neck ( except 
tumours of the parotid 
gland, nasal cavity, 





Intervention group: 7.5ml b.i.d of 
echium oil (BioMega SDA®, 
containing 235mg/ml ALA + 95mg/ml 
SDA + 79mg/ml GLA) 
Control group: 7.5ml b.i.d of sunflower 
oil (Sunflower Oil High Oleic) without 
n-3 fatty acids. 
Follow-up weekly for 7 weeks 
Weight 
BIA: LBM 
(BIA 101; DXA;) 
Hand grip strength 
(JAMAR®) 
No significant difference in weight loss was 
observed between the I group and C group 
(8.9% and 7.6%, p=0.303); 
After 4 weeks, a significant decrease in 
FFM (I= -5.10%, C= -4.12%, p<0.01), 
LBM (I= -3.77%, C= -2.41%, p<0.01) and 
FM ((I:-4.04%, C:-3.66%, P<0.05) was 
observed with DXA; 
Relative median decrease in grip strength 
was comparable between groups (I= -
0.86%, C= -0.78%, p>0.05) 
ALA: α-linolenic acid; BIA: Bioelectric Impedance Analysis; DHA: docosahexaenoic acid; DLH: doubly labelled water; DXA: dual energy X-ray 
absorptiometry; EEA: energy expenditure of activity; EORTC: European Organisation for Research and Treatment of Cancer (Quality of Life 
Questionnaire-C30 version 3.0); EPA: eicosapentaenoic acid; FAACT: Functional Assessment of Anorexia/Cachexia; FM: fat mass; FFM: free fat 
mass; GLA: γ-linolenic acid; LBM: lean body mass; MA: megestrol acetate; MM: muscle mass; MUAMC: mid-upper arm muscle circumference; 
MUAC: mid-upper arm circumference; NCCTG: North Central Cancer Treatment Group; NS: not significant; NSCLC: non-small cell lung cancer; 
ONS: oral nutricional supplement; PAL: physical activity level; PAM: physical activity monitor; REE: resting energy expenditure; SDA: stearidonic 







Seven studies provided data from 1155 patients, met the selection criteria and 
were included. In five studies, the intervention group received cans of supplement 
enriched with EPA or EPA + DHA vs the control group that received similar 
supplements as the intervention group, but without EPA or DHA. One study (17) 
evaluated the differences of outcomes between MA alone, EPA alone and MA + EPA. 
In another study (20) the intervention group received echium oil and the control group 
receive sunflower oil. The outcomes evaluated were weight, body composition (BIA), 
MUAMC, Quality of Life (EORTC-QLQC30 and Karnofsky), physical activity, 
handgrip strength, REE, appetite, survival and CRP. The follow-up ranged between 4 
and 8 weeks, and the study by Jatoi, et al 2004, lasted up to 3 months. 
 
Statistically positive intervention 
Only one study (14,15) showed both statistically and clinically positive 
intervention; 42 patients with stage III NSCLC were enrolled and allocated to the 
intervention or control group, and 40 eligible patients were included. This stage 
corresponded to patients with localised or loco-regional disease, which received 
multimodal treatment (concurrent chemo-radiotherapy), followed by surgery with 
curative intent. Stage IV NSCLC patients were not included, had the shortest survival 
and were treated by palliative chemotherapy. These patients received 2 cans/day of 
either a protein- and energy-dense oral nutritional supplement containing n-3 PUFA, 
providing 2.02 g/d EPA+0.92 g/d DHA (480 mL ProSure®) or an isocaloric control oral 
nutritional supplement without EPA and DHA (400mL Ensure®) during 5 weeks from 
the start of concurrent chemo-radiotherapy. The results showed that patients consumed 
supplements only  ̴ 1 can/day during chemo-radiotherapy. 
The outcomes described in the 2010 trial (14) were weight, Fat Free Mass 
(FFM), Mid-Upper Arm Circumference (MUAC) and Resting Energy Expenditure 
(REE). After 1, 2 and 4 weeks, the intervention group (IG) had a better weight 
maintenance than the control group (CG), (B(absolute differences between the IG and 
CG)=1.1kg, p=0.07; B=1.3kg, p=0.02; and B=1.3kg, p=0.02;) this effect was stronger in 
the per protocol analysis (B=2.2 kg, p<0.01; B=2.2kg, p<0.01; and B=2.2kg, p=0.04, 
respectively). Besides that, when selecting patients with increased plasma phospholipid 
EPA concentrations, a more adequate preservation of body weight was shown, 
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confirming that these effects could be ascribed to n-3 fatty acids supplementation. Over 
time, FFM in both groups decreased, but less in the IG than in the CG after 3 and 5 
weeks (B=1.5kg, p=0.05 and B=1.9kg, p=0.02, respectively). The MUAC of the IG 
increased during chemo-radiotherapy, tending to be ̴ 1 cm wider after 5 weeks, whereas 
MUAC in the CG decreased (p=0.06). At baseline, REE of the study population was 
112% of predicted and not significantly different between groups. Compared with the 
CG, the REE in the IG decreased more after 3 weeks (REE= -16.7% of predicted, 
p=0.01). 
The outcomes described in 2012 trial (15) were QoL and functional status 
(performance status, handgrip strength and physical activity). In general, patients in the 
IG had better on QoL scores than patients in the CG. After 3 weeks, the IG had a higher 
Karnofsky Performance Status (KPS) (B=5.3, p=0.04) than the CG. After 5 weeks, KPS 
did not differ between groups, but the IG showed a significantly better global health 
status (B=12.2, p=0.04), physical function (B=11.6, p<0.01), cognitive function 
(B=20.7, p<0.01) and social function (B=22.1, p=0.04) on the EORTC-QLQC30 
subscales vs the CG. During week 3 and 5, the IG tended to also have a considerably 
higher daily physical activity score (B=6.6, p=0.04 and B=2.5, p=0.05, respectively), 
but handgrip strength did not significantly differ between groups. 
The required number of patients (as indicated by power calculations) was not 
achieved in the IG. This might have resulted in a reduced statistical power. However, 
consistent beneficial effects of n-3 fatty acids were observed on different nutritional 
variables in this small, pre-cachectic study population. The compliance was also lower 
than expected, due to anorexia, palatability and early satiety, and patients’ preference to 
consume normal oral food rather than oral nutritional supplements. This confirms the 
need to develop more feasible methods of n-3 fatty acids supplementation for cancer 
patients. Compared with previous studies, the present study population showed a less 
advanced stage of disease and a low prevalence of malnutrition at baseline. Yet, more 
patients showed signs of pre-cachexia, such as increased levels of serum IL-6 and CRP, 
anorexia, and reduced muscle strength. 
 
Statistically negative intervention 
Moses, et al 2004 compared the effects of an EPA containing nutritional 
supplement with those of an isocaloric, isonitrogenous control supplement on weight, 
17 
 
Lean Body Mass (LBM) and QoL in patients with pancreatic cancer cachexia. A total of 
24 patients were included in the study if they had lost more than 5% of their pre-illness 
stable weight over the previous 6 months. They were asked to consume two cans/day 
for an 8-week period. Supplements were cans of 237mL with or without 1.1g of EPA. 
The mean intake of the control supplement was 1.5 cans/day and that of the EPA 
enriched supplement was 1.9 cans/day. At baseline, patients had a significantly elevated 
REE when compared with predicted values. Conversely, their Energy Expenditure of 
Activity (EEA) and Total Energy Expenditure (TEE) were significantly lower than 
predicted. Compared with baseline values, there were no significant changes in weight 
or LBM in either group over the 8-week period. However, TEE, EEA and Physical 
Activity Level (PAL) all increased significantly in those randomised to the n-3 enriched 
supplement, but not in the CG. There were however, no statistically significant 
differences between groups. Compared with baseline, energy and protein intake also 
increased significantly in those randomised to the n-3 enriched supplement. The net 
increase in both protein and energy intake in patients taking the n-3 enriched 
supplement seemed to translate into an almost parallel increase in TEE with a 
consequent rise in PAL. 
Megestrol Acetate (MA) is a synthetic derivate of progesterone (9) with proven 
efficacy in increasing appetite and non-fluid weight. It is currently considered the most 
effective available treatment option for cancer-related cachexia, being the only drug 
approved in Europe (11). In the study by Jatoi, et al 2004 the aim was to determine 
whether EPA either alone or in combination with MA improved weight, appetite, QoL, 
and survival in advanced cancer patients with cachexia, compared with MA alone; 421 
patients were deemed eligible and the median number of days on study was slightly 
more than 3 months. The study compared 3 treatment arms: an EPA supplement (2 
cans/day) plus a placebo liquid suspension that seemed identical to MA vs MA liquid 
oral suspension of 600mg/day plus isocaloric, isonitrogenous supplement that seemed 
identical to the EPA one vs two cans/day of EPA supplement plus MA liquid oral 
suspension 600 mg/day. Each EPA supplement provided 1.09g of EPA and 0.46g of 
DHA. Patients were required to have a self-reported, 2-month weight loss of at least 
2.3kg and/or a physician-estimated caloric intake of less than 20 calories/kg of body 
weight/day. The primary end point was a 10% weight gain above baseline. The 
percentage of patients who experienced such physician-reported weight gain was as 
follows: 6%, 18%, and 11% EPA-treated, MA-treated, and combination-treated arms, 
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respectively (p=0.01). Thus, the primary end point of this trial indicated greater efficacy 
of the single-agent MA. However, when weight gain was evaluated with increments of 
less than 10% weight increase, there seemed to be no significant differences among the 
arms. Appetite, as measured by the North Central Cancer Treatment Group (NCCTG) 
questionnaire, showed roughly comparable effects among groups. In contrast, the 
Functional Assessment of Anorexia/Cachexia (FAACT), suggested that appetite 
improved over time in the arms that included MA. The fact that the NCCTG 
questionnaire did not find statistically significant differences in the appetite stimulation 
degree among treatment arms, suggests that the EPA supplement might actually carry at 
least modest orexigenic effects. There were no statistically significant differences in 
median survival in EPA-treated, MA-treated, and combination-treated arms (p=0.82). 
With regard to global QoL, the Uniscale also detected no significant differences 
(p=0.93). This trial did not include a pure placebo arm. Hence, MA might have masked 
some of the favourable effects of EPA. 
Fearon, et al 2006 aimed to examine the effects of two distinct doses of EPA: 
2g/day and 4g/day of a 95% pure EPA diethyl ester against placebo, taken as capsules 
over a period of at least 8 weeks. Patients surviving beyond 8 weeks were offered EPA 
diethyl ester on a compassionate use, open label basis. Recruited patients had 
gastrointestinal and lung cancer with 5% or more loss of pre-illness stable weight. At 
baseline, patients had lost approximately 18% of their pre-illness weight and had a BMI 
of about 21 kg/  (indicating moderately severe undernutrition). Overall, 518 patients 
were recruited; the number of patients remaining in the study decreased by 
approximately 50% over 8 weeks. The primary endpoint was defined as change in body 
weight (this study was designed to detect a 2kg difference in body weight in the EPA-
supplemented group compared with the controls), between baseline and week 8. 
Secondary endpoints were survival, changes in LBM, QoL, performance status and 
CRP between baseline and week 8. Analysis of covariance for weight between the 2 
groups at 8 weeks was borderline non-significant (p=0.066). When compared with the 
placebo group, the mean weight change for the group receiving 2g/day of EPA was an 
increase of 1.2kg. The Confidence Intervals were consistent with a clinically relevant 
treatment effect for EPA at this dose. For the group receiving 4g/day of EPA, the mean 
weight change was an increase of 0.3kg. Compared with weight at baseline, patients 
receiving placebo lost a mean of 0.7kg over 8 weeks. Those receiving 2g EPA daily 
gained a median of 0.4kg and those receiving 4g EPA lost a median of 0.4kg. The 
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weight of patients with gastrointestinal cancer who received EPA, increased 
significantly compared with placebo. In contrast, the weight of those patients with lung 
cancer showed no significant response. However, there was no demonstration that the 
two groups were responding differently to EPA, because a test of interaction was not 
significant (p=0.155). A possible explanation for this, could be the differential 
expression of pro-inflammatory cytokines and other pro-cachectic molecules in 
different cancer types. Analysis of covariance for LBM between the 3 groups in the 
intention-to-treat analysis at 8 weeks, showed a non-significant result (p=0.14). When 
compared with the placebo group, the mean change in LBM for the group receiving 
2g/day of EPA was an increase of 0.9kg. For the group receiving 4g/day of EPA, LBM 
decreased of 0.1kg. Compared with LBM at baseline, patients receiving placebo lost a 
mean of 0.3kg over 8 weeks. Those receiving 2g/day of EPA gained a median of 0.6kg 
and those receiving 4g of EPA lost a median of 0.4kg. There was a statistically 
significant difference in physical function at 8 weeks between the study groups and 
those receiving placebo. Physical function improved by approximately 7% compared 
with placebo in those receiving 2g EPA (p=0.04) and fell by around 5% in those 
receiving 4g EPA. There was also a trend toward a difference in levels of self-reported 
weakness between experimental groups vs placebo. Weakness tended to decrease in the 
2g EPA group at 4 and 8 weeks, whereas there was little change in the 4g EPA group. 
Median survival from baseline of patients receiving placebo was 140 days. Patients 
receiving 2g EPA had a median survival of 155 days, and those receiving 4g EPA had a 
median survival of 142 days. There were no differences in CRP, albumin, KPS or 
appetite between groups or at any time point in either the intention-to-treat or per-
protocol groups. No benefits were observed with 4g EPA per day diethyl ester 
preparation, but a potentially clinically relevant treatment effect with 2g EPA per day. 
One explanation might be that a higher dose of EPA gave rise to nonspecific 
gastrointestinal adverse effects, which might have caused a net decline in food intake 
and hence nutritional status. However, in this study, self-reported levels of 
gastrointestinal symptoms were similar at 4 weeks and 8 weeks in the 3 groups, 
suggesting that any adverse effects of 4g per day of EPA diethyl ester were relatively 
subtle. Future cachexia trials would benefit from studying a single tumour type in an 
earlier stage disease. 
 The study by Pastore, et al 2014 aimed to evaluate compliance of cancer 
patients to EPA enriched supplementation at the beginning of chemotherapy and its 
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effects on inflammation. Overall 69 patients with gastrointestinal tract or lung cancer 
were recruited, who were about to initiate their first course of chemotherapy. There 
were 57 patients in the intention-to-treat analyses, and 43 patients in protocol analyses. 
Patients were instructed to take Oral Nutritional Supplement (ONS), 3 days before the 
first chemotherapy course and to continue taking it daily for 4 weeks. IG: three 125mL 
units enriched with 2.2g EPA/day; and CG: two 200mL units of standard ONS. After 
this period, patients returned for the final evaluation of their clinical data, nutritional 
assessment, and CRP measurements. In the intention-to-treat analysis, the IG had a 
variation of -0.5mg/dL between the onset and final CRP values; whereas in the CG, 
variation was -0.7mg/dL, (p=0.6). However, in the per protocol analysis, we observed a 
variation of -2.35mg/dL in the IG and -0.7mg/dL in the CG, showing a non-significant 
trend toward a decrease in the EPA group (p=0.8). The absence of significance could be 
due to a lack of statistical power because of the small sample size. Regarding the initial 
inflammation level according to the cancer location, lung tumours showed the highest 
CRP levels (58), followed by colon/rectum tumours (14.9), whereas pancreas and 
gallbladder tumours showed a median CRP of 0.8. This difference was not related to the 
stage of the disease (p>0.5). This finding suggests that not all types of tumours have the 
same inflammatory response profile, and some of them like lung cancer, may need 
higher amounts of EPA supplementation to modulate inflammation. Besides the fact 
that the protocol dose for the EPA supplement used in this study was 2.2g/day, a 
substantial number of patients interrupted the treatment or reduced their daily dose. 
Therefore, results might have been affected by insufficient EPA intake. Greater disease 
severity on more that 50% of the sample, may have also contributed to lack of effect of 
EPA in such serious condition.  
Echuim oil is a plant-based alternative extracted from the seeds of Echium 
plantagineum, containing significant amounts of the n-3 PUFA α-linolenic acid (ALA) 
and stearidonic acid (SDA), as well as n-6 PUFA γ-linolenic acid (GLA) and has been 
suggested as an alternative for vegetarians to benefit from the anti-inflammatory effects 
of long-chain n-3 polyunsaturated fatty acids (LCPUFA). SDA is the product of the 
rate-limiting Δ6-desaturase step and therefore more readily converted to EPA, than 
when consuming ALA (conversion rate 17-30% vs 0.2-8%). Moreover, supplementation 
with SDA in combination with GLA has been suggested to work synergistically in 
increasing anti-inflammatory effects through increases in EPA and dihomo-GLA 
(DGLA) concentrations.  
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A study by Pottel et al, 2014 primarily aimed to examine the effect of echium oil 
as an alternative source of n-3 PUFA, to reduce weight loss in head-neck (HN) cancer 
patients undergoing curative radio-chemotherapy. Of the 85 patients who initiated the 
dietary supplement, body weight loss was collected in 83 of them. Patients in the IG 
were asked to consume 7.5mL/day of echium oil (containing 235mg/mL ALA + 
95mg/mL SDA + 79mg/mL GLA) from treatment initiation, until the end of their 7-
week treatment. Patients in the CG received a placebo, containing the same volume of 
n-3 PUFA deficient sunflower oil. No significant difference in weight loss was observed 
between the IG (8.9%) vs the CG (7.6%) (p=0.303). After 4 weeks of dietary 
supplement intake, a significant decrease in FFM was seen (IG: -5.10%, CG: -2.41%, 
p<0.01), Lean Mass (LM) (IG: -3.77%, CG: -2.41%, p<0.01) and Fat Mass (FM) (IG:-
4.04%, CG:-3.66%, p<0.05) was observed in both groups with Dual energy X-ray 
Absorptiometry (DXA) evaluation (gold standart). The relative median decrease in grip 
strength throughout treatment was comparable between both groups (IG: -0.86% vs CG: 
-0.78%, p>0.05). Based on conversion rates observed in healthy people, one could argue 
that consumption of the echium oil as applied in this trial would result in a daily EPA 
dosage that is approximately half of the minimum effective dosage of 1.5g. The 
required daily echium oil volume intake would significantly have to increase in order to 
obtain comparable dosages EPA as found in fish oil (e.g. 2.4g EPA would required 
60mL echium oil). Intake of larger volumes of echium oil might not be feasible under 
radio-chemotherapy, but administration of echium oil already at time of diagnosis or 
after the end of treatments, may possibly increase patient adherence and might therefore 
be worth exploring in the future. 
 
Discussion 
Multiple biologic pathways are involved in cachexia, including immune 
response, neuroendocrine hormones and tumour specific factors such as PIF. Omega-3 
is known to reduce synthesis and secretion of cytokines, attenuate protein degradation 
by preventing NF-kB accumulation in the nucleus and inhibit the effects of PIF. 
Therefore, it would be expected that omega-3 have a role in nutritional support of 
cancer patients and attenuate the weight loss or even lead to weight gain, increase 
appetite, improve QoL and prolong survival.  
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Of note that all 7 study comprehensively discussed in this article have high 
quality (>3 point) using the Delphi List (21). The only study that was statistically 
positive (14,15) was also the only that was undertaken in a pre-cachectic study 
population, with a less advanced disease stage and a low prevalence of malnutrition at 
baseline. The other 5 studies was statistically negative. In Moses et al, 2004, patients 
were included in the study if they had lost more than 5% of their pre-illness stable 
weight over the previous 6 months. There were no significant changes in weight or 
LBM in either group, but TEE, EEA, PAL and energy+protein intake all increased 
significantly in those randomised to the n-3 enriched supplement, but not in the control 
group, over the 8-week period.  
In the clinical trial by Jatoi, et al, 2004, patients were required to have a self-
reported, 2-month weight loss of at least 2.3kg and/or a physician-estimated caloric 
intake of less than 20 calories/kg of body weight/d and the primary end point was a 10% 
weight gain above baseline. The primary end point indicated greater efficacy with 
single-agent Megesterol Acetate. However, when weight gain was evaluated with 
increments of less than 10% weight increase, there seemed to be no significant 
differences among the arms. MA is known to improve appetite and weight (increase in 
fat mass). In this study there were no differences in appetite among treatment arms, 
suggesting that the EPA supplement might actually carry at least modest orexigenic 
effects. In the other hand, when weight was evaluated with increments of less than 10%, 
there were no significant differences, which mean that EPA supplement also increase or 
stabilize weight, and it seems likely that MA might have masked some of the favourable 
effects of EPA. 
In the study by Fearon et al, 2006, patients had gastrointestinal and lung cancer 
and weight loss of 5% or more of pre-illness stable weight. At baseline, patients had lost 
approximately 18% of their pre-illness body weight and had a BMI of about 21 kg/  
(indicating moderately severe undernutrition). This study compared two doses of EPA 
(2 and 4g) with the placebo group. There was an increase in LBM, a decrease in 
weakness and a statistically significant difference in physical function in the 2g EPA 
group. It was also seen that the weight of patients with gastrointestinal cancer increased 
significantly compared with lung cancer. A possible explanation for this could be the 
different expression of pro-inflammatory cytokines and other pro-cachectic molecules 
in different cancer types.  
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In the study by Pastore, et al 2014, patients had a more advanced stage. There 
was a non-significant trend toward a decrease of CRP values in the EPA group. The 
absence of significance could be due to a lack of statistical power because of the small 
sample size. Regarding the initial inflammation level, lung tumours showed highest 
CRP levels (58), followed by colorectal tumours (14.9), whereas pancreas and 
gallbladder tumours showed median CRP of 0.8. This difference was not related to the 
stage of the disease. This finding suggests again that different types of tumours show 
different inflammatory response profile, and lung cancer may need higher amounts of 
EPA supplementation to achieve an inflammatory modulation. 
Finally, in the study by Pottel, et al, 2014 examined the effect of echium oil as 
an alternative source of n-3 PUFA. There were no differences between groups, which 
could be because the required daily echium oil volume intake would significantly have 
to increase in order to obtain comparable dosages EPA as found in fish oil.  
Future cachexia trials, would likely benefit from studying a single tumour type, 
at an earlier stage disease, and different dosage depending on the type and inflammation 
profile. Intervention in patients undergoing radio or chemotherapy may lead to a 
decrease in compliance, with interruption in the treatment or reduction in their daily 
dose. It is possible that patients associate the side effects of chemotherapy (taste change, 
loss of appetite, nausea, vomiting and sore mouth) to EPA supplementation. Therefore, 
the results of the studies may be affected by an insufficient EPA dose ingestion. Perhaps 
a better adherence could be obtained if EPA was given after adaptation to 
chemotherapy, when patients are able to recognize its side effects, thus avoiding a 
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